Woodland Hills, CA, United States of America

Dennis J Slamon

This inventor holds 24 USPTO granted patents and 21 published patent applications and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: University of California, 1200 Pharma LLC, California Institute of Technology. Active years: 1987-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis J Slamon. Retrieved from https://idiyas.com/inventor/dennis-j-slamon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 21)

% Patents Active = 83.3

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 3.1

ph-index = 11

Forward Citations = 745(Granted Patents)

Location History:

Woodland Hills, CA (US) (1987 - 2011)
Los Angeles, CA (US) (2023 - 2024)

Company Filing History:

22 out of 16,025

University of California

California Institute of Technology

patents

4. 1 out of 3,742

Bristol-Myers Squibb Compnay

6. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1987-2026

Loading Chart...

Areas of Expertise:

PRMT5 Inhibitors

CDK Inhibitors

ERK Inhibitors

Claudin-6 Antibodies

Claudin-18 Antibodies

Tumor Suppressor Gene

HER-2/neu Overexpression

Frozen Tissue Microarray

Predictive Markers

Gene Amplification

Cancer Treatment

Diagnostic Methods

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583859 - PRMT5 inhibitors and uses thereof (2026-03-24),

2. 12486280 - CDK inhibitors and uses thereof (2025-12-02),

3. 12428416 - ERK inhibitors and uses thereof (2025-09-30),

4. 12403202 - Dosage of claudin-6 conjugates for cancer treatment (2025-09-02),

5. 12345709 - CLAUDIN18 antibodies and methods of treating cancer (2025-07-01),

6. 12065489 - Claudin-6 antibodies and drug conjugates (2024-08-20),

7. 11834499 - Claudin18 antibodies and methods of treating cancer (2023-12-05),

8. 8007995 - Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers (2011-08-30),

9. 7537905 - Amplified and overexpressed gene in colorectal cancers (2009-05-26),

10. 7314916 - Methods and materials for characterizing and modulating interaction between heregulin and HER3 (2008-01-01),

11. 7125680 - Methods and materials for characterizing and modulating interaction between heregulin and HER3 (2006-10-24),

12. 6929910 - Diagnostic and therapeutic methods using the H37 tumor suppressor gene (2005-08-16),

13. 6893837 - Frozen tissue microarray technology for analysis RNA, DNA, and proteins (2005-05-17),

14. 6770477 - Differentially expressed genes associated with HER-2/neu overexpression (2004-08-03),

15. 6767541 - HER-2/neu overexpression abrogates growth inhibitory pathways (2004-07-27),

Title: The Innovative Work of Dennis J. Slamon

Introduction

Dennis J. Slamon is an esteemed inventor located in Woodland Hills, CA, known for his significant contributions in the field of cancer research and antibody development. With a remarkable portfolio of 19 patents, Slamon's work has paved the way for new therapeutic options in oncology.

Latest Patents

Among his latest patents are innovations regarding Claudin-6 antibodies and drug conjugates. This work provides antigen-binding proteins that target Claudin-6 (CLDN6), specifically binding to the Extracellular Loop 2 (EL2) of its extracellular domain. The patent encompasses related polypeptides, nucleic acids, vectors, host cells, and conjugates, along with methods for creating these proteins and treating subjects with cancer. Another significant patent focuses on Claudin-18 antibodies and methods for cancer treatment. This disclosure includes antigen-binding proteins that target Claudin-18.2 (CLDN18.2), bispecific proteins that bind to CLDN18.2 and another antigen, and additional related compositions.

Career Highlights

Slamon has made notable advancements while working at the University of California and Sugen Incorporated. His innovative research and developments in antibody therapeutics have had a profound impact on treatment methodologies for cancer, providing both hope and tangible advancements in medical science.

Collaborations

Throughout his career, Slamon has collaborated with several accomplished professionals, including Klaus Peter Hirth and Donna Pruess Schwartz. These collaborations have further enriched his research and fostered significant developments in the field of biomedicine.

Conclusion

In conclusion, Dennis J. Slamon's contributions to the field of cancer research through his numerous patents highlight his status as a leading inventor. His work not only expands the boundaries of scientific knowledge but also plays a crucial role in advancing treatment options for patients with cancer. His innovative spirit and collaborative efforts ensure a lasting impact in the medical community.

Profile summary based on public USPTO records.